Q4 Earnings Forecast for Moderna Issued By Leerink Partnrs

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Research analysts at Leerink Partnrs issued their Q4 2025 earnings estimates for shares of Moderna in a research note issued on Monday, January 13th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings per share of ($2.54) for the quarter. The consensus estimate for Moderna's current full-year earnings is ($9.30) per share. Leerink Partnrs also issued estimates for Moderna's FY2028 earnings at ($2.70) EPS and FY2029 earnings at ($0.07) EPS.

Several other brokerages also recently commented on MRNA. Jefferies Financial Group decreased their target price on shares of Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research note on Tuesday, October 15th. Royal Bank of Canada restated a "sector perform" rating and issued a $75.00 price objective on shares of Moderna in a research report on Thursday, September 19th. JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $59.00 to $45.00 and set an "underweight" rating for the company in a research note on Tuesday, November 26th. HSBC raised Moderna from a "hold" rating to a "buy" rating and set a $58.00 target price on the stock in a research note on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a research report on Friday, November 8th. Four equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Moderna currently has an average rating of "Hold" and a consensus price target of $76.68.

Moderna Trading Up 0.9 %

Moderna stock traded up $0.31 during trading hours on Wednesday, reaching $34.77. The company had a trading volume of 7,451,588 shares, compared to its average volume of 13,017,716. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna has a 12-month low of $31.94 and a 12-month high of $170.47. The company has a 50-day moving average price of $41.44 and a 200 day moving average price of $67.56. The firm has a market cap of $13.38 billion, a price-to-earnings ratio of -5.97 and a beta of 1.60.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company's quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.39) earnings per share.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the company's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 in the last ninety days. 15.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Moderna

A number of institutional investors and hedge funds have recently bought and sold shares of MRNA. Axiom Advisory LLC grew its holdings in shares of Moderna by 1.6% during the third quarter. Axiom Advisory LLC now owns 12,672 shares of the company's stock valued at $847,000 after buying an additional 198 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in Moderna during the 2nd quarter valued at $26,000. Arkadios Wealth Advisors increased its holdings in shares of Moderna by 2.2% in the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company's stock worth $764,000 after purchasing an additional 243 shares in the last quarter. Knuff & Co LLC raised its stake in shares of Moderna by 5.4% in the third quarter. Knuff & Co LLC now owns 4,732 shares of the company's stock worth $316,000 after purchasing an additional 244 shares during the last quarter. Finally, Stephens Inc. AR lifted its holdings in shares of Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company's stock valued at $223,000 after purchasing an additional 245 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.